Prognosis in adults with ph-positive B-ALL in first complete remission without minimal residual disease after blinatumomab consolidation is influenced by minimal residual disease (≥10-4) pre-blinatumomab
Benjamin Frost(Brigham and Women's Hospital), Evan C. Chen(Dana-Farber Cancer Institute), Maximilian Stahl(Harvard University), Kuo‐Kai Chin(Memorial Sloan Kettering Cancer Center), Marlise R. Luskin(Dana-Farber Cancer Institute), Yael Flamand(Dana-Farber Cancer Institute), Mark B. Geyer(Memorial Sloan Kettering Cancer Center), Martha Wadleigh(Dana-Farber Cancer Institute), Shai Shimony(Twitter (United States)), Eytan M. Stein(Memorial Sloan Kettering Cancer Center), Virginia O. Volpe(UConn Health), Richard M. Stone(Dana-Farber Cancer Institute), Leora Boussi(Beth Israel Deaconess Medical Center), David Nemirovsky(Memorial Sloan Kettering Cancer Center), Andriy Derkach(Memorial Sloan Kettering Cancer Center), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Meira Yisraeli Salman(Memorial Sloan Kettering Cancer Center), Yannis K. Valtis(Brigham and Women's Hospital), Jae-Hong Park(Dong-A University Hospital), Emilie Baxter(Harvard University), Jacqueline S. Garcia(Dana-Farber Cancer Institute), Natalia Tijaro Ovalle(Kettering University), Eric S. Winer(Providence College)
Cited by 0
Related Papers
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k